Avicanna Inc (TSE:AVCN) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Avicanna Inc. celebrates a landmark financial milestone with its first positive EBITDA quarter in Q1 2024, boasting a 451% year-over-year revenue surge to $6.45 million, alongside a record 51% gross margin. The company’s success is attributed to its medical cannabis business, operational efficiencies, and the introduction of new products in Canada. Additionally, Avicanna expands its international footprint with the Colombian approval of its epilepsy drug Trunerox™ and secures strategic agreements to supply proprietary topical products in Europe.
For further insights into TSE:AVCN stock, check out TipRanks’ Stock Analysis page.
